Trial record 1 of 1 for:
eortc 1559 upstream
Biomarker-based Study in R/M SCCHN (UPSTREAM)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03088059 |
|
Recruitment Status :
Active, not recruiting
First Posted : March 23, 2017
Last Update Posted : November 3, 2023
|
Sponsor:
European Organisation for Research and Treatment of Cancer - EORTC
Information provided by (Responsible Party):
European Organisation for Research and Treatment of Cancer - EORTC
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Brief Summary:
This is a biomarker-driven trial that will enroll patients with recurrent or metastatic squamous cell carcinoma of the head and neck progressing after first-line platinum-based chemotherapy. Based on potential biomarkers and molecular alterations identified in the biopsy from the central platform, patients will be allocated in different cohorts. There will be biomarker-positive patient cohorts and immunotherapy cohorts.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Carcinoma, Squamous Cell of Head and Neck | Drug: Afatinib Drug: Palbociclib Drug: standard of care Drug: IPH2201 Drug: Durvalumab Drug: Niraparib Drug: INCAGN01876 | Phase 2 |
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 340 participants |
| Allocation: | Non-Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | A Pilot Study of Personalized Biomarker-based Treatment Strategy or Immunotherapy in Patients With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck |
| Actual Study Start Date : | November 16, 2017 |
| Estimated Primary Completion Date : | June 2025 |
| Estimated Study Completion Date : | December 2025 |
Resource links provided by the National Library of Medicine
MedlinePlus Genetics related topics:
Head and neck squamous cell carcinoma
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Patient Cohort B1
Patients who are p16 negative and have an EGFR amplification/mutation or PTEN high or HER2 mutation/amplification will be randomized between afatinib or the standard of care (Methotrexate, Paclitaxel, Docetaxel, Carboplatin, 5-Fluorouracil, Bleomycine, Gemcitabine, Mitomycine or Best supportive care).
|
Drug: Afatinib
Afatinib 40 mg given orally, once daily, 1 cycle is 28 days Drug: standard of care Methotrexate, Paclitaxel, Docetaxel, Carboplatin, 5-Fluorouracil, Bleomycine, Gemcitabine, Mitomycine or Best supportive care |
|
Experimental: Patient Cohort B2
Patients who are p16 negative and cetuximab naïve will be randomized between afatinib or the standard of care (Methotrexate, Paclitaxel, Docetaxel, Carboplatin, 5-Fluorouracil, Bleomycine, Gemcitabine, Mitomycine or Best supportive care)
|
Drug: Afatinib
Afatinib 40 mg given orally, once daily, 1 cycle is 28 days Drug: standard of care Methotrexate, Paclitaxel, Docetaxel, Carboplatin, 5-Fluorouracil, Bleomycine, Gemcitabine, Mitomycine or Best supportive care |
|
Experimental: Patient Cohort B3
Patients who are p16 negative and have an amplification of CCND1 will be randomized between palbociclib or the standard of care (Methotrexate, Paclitaxel, Docetaxel, Carboplatin, 5-Fluorouracil, Bleomycine, Gemcitabine, Mitomycine or Best supportive care)
|
Drug: Palbociclib
Palbociclib 125 mg given orally, once daily, 1 cycle is 28 days (21 days on treatment, then 7 days off) Drug: standard of care Methotrexate, Paclitaxel, Docetaxel, Carboplatin, 5-Fluorouracil, Bleomycine, Gemcitabine, Mitomycine or Best supportive care |
|
Experimental: Patient Cohort B4
Patients who are p16 negative and 'platinum sensitive' SCCHN will receive niraparib
|
Drug: Niraparib
Niraparib 300 mg given orally, once daily, 1 cycle is 28 days |
|
Experimental: Patient Cohort B5
Patients whith oropharyngeal cancer and which are p16 positive will receive niraparib
|
Drug: Niraparib
Niraparib 300 mg given orally, once daily, 1 cycle is 28 days |
|
Experimental: Patient Cohort I1
Patients who are anti-PD(L)1-naïeve or resistant (primary or secondary resistance) will receive IPH2201 antibody (monalizumab).
|
Drug: IPH2201
protocol v2.0 and 2.1 : Monalizumab 10mg/kg given intravenously over 60 minutes, once every 14 days, 1 cycle is 14 days protocol v4.0 : Monalizumab 750mg given intravenously over 60 minutes, once every 28 days, 1 cycle is 28 days
Other Name: Monalizumab |
|
Experimental: Patient Cohort I2
Patient who are PD(L)1 pretreated will be randomized between monalizumab + durvalumab or the standard of care (Methotrexate, Paclitaxel, Docetaxel, Carboplatin, 5-Fluorouracil, Bleomycine, Gemcitabine, Mitomycine or Best supportive care)
|
Drug: standard of care
Methotrexate, Paclitaxel, Docetaxel, Carboplatin, 5-Fluorouracil, Bleomycine, Gemcitabine, Mitomycine or Best supportive care Drug: IPH2201 protocol v2.0 and 2.1 : Monalizumab 10mg/kg given intravenously over 60 minutes, once every 14 days, 1 cycle is 14 days protocol v4.0 : Monalizumab 750mg given intravenously over 60 minutes, once every 28 days, 1 cycle is 28 days
Other Name: Monalizumab Drug: Durvalumab Durvalumab 1500mg given intravenously over 60 minutes, once every 28 days, 1 cycle is 28 days |
|
Experimental: Patient Cohort I3
Patient who are progressing prior PD(L)1 after having received at least 2 months of anti-PD(L)-1 will receive INCAGN01876.
|
Drug: INCAGN01876
INCAGN01876 300 mg given intravenously over 30 minutes, once every 14 days, 1 cycle is 28 days |
Primary Outcome Measures :
- Progression Free Survival Rate (PFSR) at week 16 [ Time Frame: The Progression Free Survival Rate (PFSR) analysis will be performed at week 16 for each patient in cohorts 1, 2 and 3. ]Progression Free Survival Rate (PFSR) at week 16 will be assessed as primary endpoint for all patients from cohorts 1, 2 and 3.
- Objective response Rate (ORR) at week 16 [ Time Frame: Objective response Rate (ORR) at week 16 will be performed at week 16 for each patient in cohort 4. ]Objective response Rate (ORR) during the first 16 weeks of study treatment will be assessed as primary endpoint for all patients from cohort 4-8.
Secondary Outcome Measures :
- Progression Free Survival (PFS) [ Time Frame: 54 months after first patient in ]
- Objective Response Rate [ Time Frame: 48 months after first patient in ]Objective Response Rate will be measured according to both RECIST 1.1 and iRECIST
- Response duration [ Time Frame: 54 months after first patient in ]
- Overall Survival (OS) [ Time Frame: 54 months after first patient in ]
- Toxicity according CTCAE version 4.03 [ Time Frame: 54 months after first patient in ]This study will use the International Common Terminology Criteria for Adverse Events (CTCAE), version 4.03, for adverse event reporting.
- Percentage of patients included in each patient cohort according the biomarker testing [ Time Frame: 42 months after first patient in ]
- The percentage of patients with an evaluable fresh tumor biopsy [ Time Frame: 42 months after first patient in ]
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
General Inclusion Criteria:
- Histologically confirmed recurrent and/or metastatic SCCHN of the oral cavity, oropharynx, hypopharynx or larynx not amenable to curative treatment.
- At least one measurable lesion by MRI or CT-scan according to RECIST 1.1, evaluated within 2 weeks prior to registration. Such lesion must not have been previously irradiated; if the measurable lesion(s) have been irradiated, clear progression must be documented.
- Progressive disease after first line platinum-based chemotherapy with or without cetuximab given as palliative treatment or progressive disease within 1 year if platinum-based chemotherapy was given as a part of the multimodal curative treatment. Patients pre-treated with anti-PD1/anti-PDL1 are allowed.
- ECOG performance status 0 -1 with a life expectancy of at least 12 weeks.
- Tumor core biopsy from any accessible tumor at the recurrent or metastatic site available for central testing.
- Patients must have adequate organ function, evaluated within 14 days prior to cohort allocation:
- Hemoglobin ≥ 9 g/100 ml,
- Neutrophils ≥ 1,500/mm3,
- Platelets ≥ 100,000/mm3,
- Total bilirubin <1.5 times the upper limit of normal (ULN) (< 3 times the upper limit of normal for Gilbert's disease),
- Serum ALT and AST ≤ 2.5 x ULN,
- Adequate renal function measured by:
- Estimated creatinine clearance ≥45ml using Cockcroft and Gault formula or Creatinine ≤ 1.5 ULN
- International Normalized Ratio (INR) or Prothrombin Time (PT) must be within the normal ranges as per institution's standard. A window of 5% is allowed.
- Patients receiving anticoagulant therapy are allowed to participate as long as the PT/INR values are within the expected target range of their current dose.
- Clinically normal cardiac function based on -left ventricular ejection fraction (≥ 50%) as assessed either by multi-gated acquisition scan or cardiac ultrasound and 12 lead ECG without clinically relevant abnormalities.
- Patients ≥ 18 years old and must be able to give written informed consent.
- Patients ≥ 70 years old must undergo the G8 screening.
- Women of child-bearing potential must have a negative pregnancy test (serum or urine within the 72 hours prior to cohort allocation).
- Patients of childbearing / reproductive potential must agree to use highly effective methods of contraception based on the Clinical Trial Facilitation Group (CTFG) guidance as of registration and up to 6 months after the last treatment dose. Highly effective methods can achieve failure rate of less than 1% per year when used consistently and correctly. Such methods include: For Women: combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation (oral, intravaginal and transdermal), progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable, implantable), intrauterine device, intrauterine hormone-releasing system, bilateral tubal occlusion, vasectomized partner and sexual abstinence. For Men: condoms, sexual abstinence (the reliability of sexual abstinence needs to be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the patient) and no sperm donations during treatment and up to 6 months after last dose of treatment.
- Female subjects who are breast feeding should agree to discontinue nursing prior to the first dose of study treatment and up to 6 months after the last study treatment.
- Before patient registration/randomization, written informed consent must be given according to ICH/GCP, and national/local regulations.
General Exclusion Criteria:
- Unresolved and significant toxicity CTCAE version 4.03 grade ≥ 2 from previous anticancer therapy other than alopecia.
- History of any of the following cardiovascular conditions within 6 months prior to registration:
- myocardial infarction,
- severe/unstable angina,
- ongoing cardiac dysrhythmias of CTCAE version 4.03 Grade 2 or more,
- atrial fibrillation of any grade,
- coronary/peripheral artery bypass graft,
- symptomatic congestive heart failure according to New York Heart Association (NYHA) Class III or Class IV,
- significant active cardiac disease including uncontrolled high blood pressure defined as systolic ≥150 and diastolic ≥100.
- cerebrovascular accident including transient ischemic attack
- thromboembolic events like symptomatic pulmonary embolism.
- Nasopharynx and sino-nasal tumor.
- Surgery or investigational drugs or chemotherapy or other anticancer therapy within 3 weeks before cohort allocationor or for investigational drugs, within a time interval less than at least 5 half-lives of the investigational agent, whichever is shorter. Participant must have recovered from any surgical procedure. Curative radiation therapy (60-70 Gy) within 6 weeks of cohort allocation. Palliative radiation therapy (e.g. 8 Gy on a painful lesion) will be allowed.
- Known untreated and uncontrolled brain metastases or leptomeningeal carcinomatosis.
- Known diagnosis of immune deficiency or a positive serology of Human Immunodeficiency Virus (HIV) (HIV 1/2 antibodies).
- Active Hepatitis B (e.g., HBsAg reactive) or Hepatitis C (e.g., HCV RNA [qualitative] is detected) or pre-existing liver cirrhosis.
- Known pre-existing interstitial lung disease (ILD). Bronchoemphysema is not considered as ILD.
- Other uncontrolled active illnesses or nonmalignant systemic disease (examples include, but are not limited to active infections requiring antibiotics, bleeding disorders, uncontrolled diabetes, uncontrolled ventricular arrhythmia, uncontrolled major seizure disorder, unstable spinal cord compression, superior vena cava syndrome …).
- Any psychiatric, psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule.
- Any malignancy (other than SCCHN, non-melanoma skin cancer or localized cervical cancer or localized and presumed cured prostatic cancer or basal cell carcinoma of the skin and carcinoma in situ of the cervix or bladder) within the last 3 years prior to treatment allocation.
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03088059
Locations
Show 36 study locations
Sponsors and Collaborators
European Organisation for Research and Treatment of Cancer - EORTC
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | European Organisation for Research and Treatment of Cancer - EORTC |
| ClinicalTrials.gov Identifier: | NCT03088059 |
| Other Study ID Numbers: |
EORTC-1559-HNCG 2017-000086-74 ( EudraCT Number ) |
| First Posted: | March 23, 2017 Key Record Dates |
| Last Update Posted: | November 3, 2023 |
| Last Verified: | November 2023 |
| Studies a U.S. FDA-regulated Drug Product: | No |
| Studies a U.S. FDA-regulated Device Product: | No |
Additional relevant MeSH terms:
|
Carcinoma Carcinoma, Squamous Cell Squamous Cell Carcinoma of Head and Neck Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type Neoplasms Neoplasms, Squamous Cell Head and Neck Neoplasms Neoplasms by Site Durvalumab |
Palbociclib Niraparib Afatinib Antineoplastic Agents, Immunological Antineoplastic Agents Protein Kinase Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Poly(ADP-ribose) Polymerase Inhibitors Tyrosine Kinase Inhibitors |